Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …

Purpose Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentration
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …

Introduction Dacomitinib and gefitinib are irreversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI) indicated for the first-line treatment of patients with …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
increasingly used for advanced non-small cell lung cancer (NSCLC) as first-line therapy …

Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …

Purpose This study aimed to examine the prognostic impact of concomitant pH-regulating
drug use in patients with epidermal growth factor receptor (EGFR)-mutation-positive non …

Background Erlotinib and gefitinib are weak base drugs whose absorption and clinical
efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton …

Background This retrospective cohort study examined the impact of tetracyclines (TCs) and
proton pump inhibitors (PPIs) alone or in combination on the efficacy of epidermal growth …

Background Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with
TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease …

Purpose: Erlotinib and gefitinib are both tyrosine kinase inhibitors (TKIs) approved for the
treatment of non-small cell lung cancer (NSCLC). Although it is well known that the increase …